Objectives-The main objective of this study was to remove amyloid b plaques by applying multiple sessions of focused ultrasound (US)-induced blood-brain barrier (BBB) opening using microbubbles with and without delivery of antibodies in a rabbit model.
A lzheimer disease (AD) is a major form of dementia. There were an estimated 44.4 million people with dementia worldwide in 2013. 1 This number will increase to an estimated 75.6 million in 2030 and 135.5 million in 2050. Much of the increase will be in developing countries. There are 7.7 million new cases of dementia each year, implying that there is a new case of dementia globally every 4 seconds. The total estimated worldwide cost of dementia was US$604 billion in 2010.
Among the brain changes believed to contribute to the development of AD is the accumulation of amyloid b (Ab) peptide outside neurons. Amyloid b is generated from the b-amyloid precursor protein. Another change is the accumulation of an abnormal form of the protein tau inside neurons (called tau tangles). In AD, information transfer at synapses begins to fail; the number of synapses declines; and neurons eventually die. Alzheimer disease is a complex and serious neurodegenerative disorder, with no established treatment; therefore, there are enormous research efforts worldwide for treatment of AD. Our study focused on the feasibility of using repeated pulsed focused ultrasound (US) in combination with antibodies as a new potential therapeutic modality.
Part of this study was immunotherapy, which is one of the promising therapeutic approaches focused on using antibodies to facilitate clearance of the Ab peptide. One mechanism that could explain the process is the soluble equilibrium mechanism, which is based on antibodies neutralizing soluble Ab and shifting the equilibrium to favor dissolution. 2 This mechanism of action usually takes place in both the periphery and central compartments. However, one limitation of delivering antibodies to the brain is the blood-brain barrier (BBB). It has been reported that that only 0.1% of exogenous antibodies administered endovascularly enter the brain. 3 Direct administration of antibodies to the brains of transgenic mice has been shown to reduce Ab plaques 4 because more antibodies reached the affected region. However, these methods are invasive, since the injection is administered through the skull. 5 The BBB is the greatest obstacle to the transport of drugs into the brain. This obstacle prohibits all large molecules and most small molecules from entering the brain. It is a limiting factor for the application of therapies in the brain. In the last decade, important studies in animal models (rabbits, mice, and monkeys) have shown that pulsed US administered with contrast agents can open the BBB for a short period with minimal side effects. [6] [7] [8] [9] [10] [11] [12] Additionally, a recent study by Papadakis et al 13 showed that the BBB not only did not change the metabolic activity of the rat brain but also preserved neural integrity. Opening the BBB by using focused US can be used as a noninvasive method for delivering drugs to the brain.
Relevant studies for AD treatment using focused US by Jordão et al 14, 15 have shown that endogenous antibodies entered the brain after BBB opening using magnetic resonance imaging (MRI)-guided focused US and eliminated cortical Ab plaques in transgenic TgCRND8 mice. Moreover, in the study by Jordão et al, 14 exogenous antibodies (BC-10) were used as a therapeutic agent against Ab plaque destruction. This transgenic animal model was chosen because it has an abundant plaque load.
In another study by Burgess et al, 16 it was shown that repeated MRI-guided focused US led to spatial memory improvement in a transgenic mouse model of AD. The behavioral changes could be attributed to decreased amyloid pathologic abnormalities and increased neuronal plasticity. Recently, Leinenga and G€ otz 17 removed Ab with repeated scanning US using a similar pulsed exposure as other groups in the mouse brain, without any therapeutic agent. The plaque burden was reduced in scanning UStreated mice with AD compared to sham-treated animals, and cleared plaques were observed in 75% of scanning US-treated mice. That study, 17 which was conducted concurrently with our study, reported an additional treatment session 1 month after the first treatment.
In our study, an animal model of AD was needed. A rabbit model fed with a high-cholesterol diet was used, which creates Ab plaques in the brain. The first study to report that a high-cholesterol diet in rabbits results in accumulation of Ab plaques was reported by Sparks et al. 18 The Ab plaques were created with a 2% cholesterol-enriched diet for up to 8 weeks. 18 The mechanism of Ab plaque development is not fully understood yet. The rabbits were euthanized at the end of the experiment because the 2% cholesterol diet caused hypercholesterolemic side effects at 8 weeks. 19 Our study included the following major tasks: Multisession (3 times) BBB opening was applied, either with focused US only or with focused US in synergy with antibodies. A comparison of the effects of treatment with focused US only and with focused US and antibodies was conducted. Since there was evidence that the BBB opening was sustained for about 3 hours, 6 and based on the evidence of the therapeutic effect of endogenous and exogenous antibodies reported by Jordão et al, 14 then it can be claimed that by opening the BBB in 3 successive sessions, an increased therapeutic effect due to the repeated entrance of these antibodies can be achieved. The rabbit AD model offered larger brain volume and larger plaque size; therefore, it could serve as a better model than the mouse model.
Materials and Methods

Animals and Diet
The animal experimental protocol was approved by the national body in Cyprus responsible for animal studies (Ministry of Agriculture, Animal Services). A total of 52 New Zealand White rabbits (3.4-4.1 kg) were used during the experiments. The rabbits were divided randomly into the following groups: In group A (n 5 3) the rabbits were fed with normal chow. The purpose of this group was to show the histologic characteristics of brain without Ab plaques. In the following groups, the animals were fed with a 2% high-cholesterol diet (T2030; Harlan Laboratories SRL, Udine, Italy) for 4 months. The daily average consumption of this specialized diet was 200 g/ rabbit. Three rabbits (group B) were euthanized without any treatment to be used as a reference for measuring the initial plaque load. Two rabbits (group C) received only antibody treatment. Two rabbits (group D) were exposed only to BBB opening with focused US to assess the effect of diffusion into the brain, possibly by endogenous antibodies or other proteins. Two rabbits (group E) were exposed to BBB opening with focused US and exogenous antibodies to assess the effect of both endogenous antibodies or other proteins and exogenous antibodies. In Group F, 16 rabbits were treated with only focused US and antibodies to study the effect of time on plaque clearance. In group G, 12 rabbits were treated with only focused US (1, 2, and 3 sessions with n 5 4 per session). In group H, 12 rabbits were treated with focused US and antibodies (1, 2, and 3 sessions with n 5 4 per session). Since the staining used required the animal to be euthanized, the contralateral side of the brain served as a control. Additionally, group B received no treatment and therefore gave an indication of the initial plaque density load. The brains of 3 rabbits underwent an enzyme-linked immunosorbent assay evaluation to confirm the creation of Ab plaques (Ab-42). Table 1 summarizes the various groups used during this feasibility study. All animals that received the high-cholesterol diet were euthanized in 4 months because severe side effects appeared (hypercholesteremic side effects such as weight loss, appetite loss, and jaundice). In addition, these rabbits at this stage had significant cognitive deficits. After delivering the high-cholesterol diet for 4 months, the creation of Ab plaques was present in all animals.
Focused US System
The focused US system was composed of a signal generator (HP 33120A; Agilent Technologies, Englewood, CO), a radiofrequency amplifier (150 W; AR, Souderton, PA), and a spherically shaped bowl transducer made from piezoelectric ceramic with a low magnetic susceptibility (Etalon; Lebanon, IN). The transducer operated at 1 MHz and had a focal length of 10 cm and a diameter of 4 cm. The welfare of the animal was monitored by an MRI-compatible camera (MRC Systems GmbH, Heidelberg, Germany).
The positioning device had 3 computer-controlled axes (x, y, and z). All of the parts of the positioning device were manufactured with a 3D printer (FDM400; Stratasys, Eden Prairie, MN). The positioning device Figure 1 shows the placement of the rabbit in the positioning device for performing in vivo experiments. The focused US system was used in an MRI scanner (Signa 1.5 T; GE Healthcare, Fairfield, CT). A spinal coil (USA Instruments, Cleveland, OH) was used to acquire the MRI signal. The opening of the BBB was imaged by contrast-enhanced T1-weighted fast spin echo MRI (repetition time, 500 milliseconds; echo time, 18 milliseconds; echo train length, 4; bandwidth, 16 kHz; matrix size, 256 3 256; number of excitations, 4; field of view, 10 cm; slice thickness, 3 mm; interslice spacing, 0.3 mm). The MRI contrast was achieved with a contrast agent (Magnevist; Berlex Laboratories, Inc, Wayne, NJ), which was injected intravenously at a dose of 0.125 mmol/kg of body weight as a bolus injection. The contrast agent was injected roughly 5 minutes after sonication, and imaging was initiated 5 minutes after the injection of the contrast agent. 
Cholesterol Measurement
The cholesterol of the rabbits was measured by extracting blood from the ear vein after overnight fasting immediately before euthanasia by the enzymatic cholesterol oxidase method (kit by Sigma Aldrich).
Histopathologic Techniques
Coronal frozen sections (20 lm) were cut from the excised brains and cut at the level of the hippocampus from treated rabbits. The sections were air dried, fixed in 10% formalin for 10 minutes, and treated with 1% hydrogen peroxide in phosphate-buffered saline. Then the sections were incubated with a blocking solution of 1.5% normal serum (Vector Laboratories, Peterborough, England). For the estimation of the amyloid plaque load, sagittal sections of 20 lm in thicknesses spanning all of the hippocampal formation were chosen for thioflavine-S staining (Sigma Aldrich). Sections were incubated for 8 minutes in an aqueous solution of thioflavine-S (1% wt/vol). The sections were then differentiated with 80% ethanol for 3 minutes and with 95% ethanol for 3 minutes. Sections were rinsed 3 times with double-distilled water. Imaging for thioflavine-S was performed on a BX 50 microscope (Olympus Optical, Tokyo, Japan).
The plaque load was measured by the freeware software ImageJ (National Institutes of Health, Bethesda, MD), which counted dots on histologic slides (10 slides per brain in the area of the hippocampus) and were stored in a digital format. The software measured dots either in an automatic mode or, in the case of dots that were very close, in a manual mode.
Measurement of Acoustic Pressure
The peak negative pressure was measured in a tank filled with degassed water. The measurement was performed with a calibrated hydrophone (HGL Series; Onda Corporation, Sunnyvale, CA). The free-field pressure field produced by the focused US transducer was measured by a 3-dimensional positioning device with the needle hydrophone. The spatial resolution was 0.1 mm in the radial direction (x-and y-axes) and 0.5 mm in the axial direction (z-axis), with measured distances of 40 and 120 mm in the z-axis and 3 mm in the radial direction. The maximum peak negative acoustic pressure measured at the focus in water was 0.8 MPa, which was equivalent to 190 W of electrical power (90 W of acoustic power). The half-pressure length of the acoustic field measured with the hydrophone was 21 mm, and the corresponding half-pressure width was 1.5 mm. The value reported for the rabbit experiments was estimated in the brain based on US attenuation of 5 Np/m/MHz 21 through a 1-cm path. A loss of 14 dB/cm/MHz was considered for the 3-mm skull, based on data reported by Pinton et al. 22 Based on the attenuation of the skull and brain tissue of the rabbit, and based on the 1-cm path, the in situ peak negative pressure was close to 0.4 MPa. This pressure was possibly decreased further because given the small size of the rabbit brain, the reflected acoustic field due to the skull base destructively distorted the beam, and as a result, the applied acoustic pressure could have been much lower than in water. Based on a study by Tung et al, 23 this pressure level does not produce substantial hemorrhage. The total power delivered by the transducer was measured before the beginning of each experiment with a US power meter (UPM-DT-100N; Ohmic Instruments, Easton, MD).
Hematoxylin-Eosin
A histologic examination using hematoxylin-eosin was performed in 3 rabbit brains. After euthanasia, the brains were removed and formalin fixed, and paraffinembedded sections were prepared with a thickness of 20 lm. Sections were stained with hematoxylin-eosin for histologic evaluation of the effects of the focused US exposure. There are many articles discussing the pressure threshold for hemorrhage during BBB opening, but either those studies used a different frequency, or the pressure indicated might not have been the minimum. Therefore, the hematoxylin-eosin test was used to ensure that hemorrhage was caused by the acoustic pressure used (0.8 MPa in water and 0.4 MPa in the rabbit brain).
Enzyme-Linked Immunosorbent Assay
A rabbit Ab-42 enzyme-linked immunosorbent assay kit (Thermo Fisher Scientific, Pittsburgh, PA) was used for the quantitative determination of Ab-42 in brain tissue using a 96-well plate and a microplate reader. The assay recognizes rabbit Ab-42. The Ab antigen binds to the immobilized (capture) antibody. The bound rabbit antibody was detected by the use of a horseradish peroxidase-labeled antirabbit antibody. After removal of excess antirabbit antibody, a substrate solution was added, which was acted on by the bound enzyme to produce color. The intensity of this color product was directly proportional to the concentration of rabbit Ab-42 present in the original specimen. Treated and untreated brain tissue from 3 rabbits was homogenized in a 20-mM Tris-buffered solution. Soluble Ab was extracted with a diethanolamine/sodium chloride solution, followed by centrifugation. The supernatant was removed and neutralized for soluble Ab analysis. The total fraction was solubilized in cold formic acid, followed by sonication and centrifugation. The supernatant was similarly collected and neutralized.
In Vivo Experiments
The rabbits were anesthetized with a mixture of 500 mg of ketamine (100 mg/mL; Aveco, Ford Dodge, IA), 160 mg of xylazine (20 mg/mL; Loyd Laboratories, Shenandoah, IA), and 20 mg of acepromazine (10 mg/ mL; Aveco) at a dose of 1 mL/kg. The rabbits were euthanized at different times depending on the study group (ranging from 1-4 days) to allow enough time for exogenous antibodies to bind to the plaques. There is evidence that the BBB remains open for 3 hours after focused US exposure. 6 The total time of sonication was 20 seconds. The pulse length was 10 milliseconds with a pulse repetition period of 1 second. One pulse sonication was needed to open the BBB. The decision to use these parameters was based on studies by McDannold et al 10 and Hynynen et al. 6 The power used was adjusted so that the peak negative pressure was set to 0.8 MPa. However, because of the skull attenuation, the actual negative pressure in the brain perhaps was much lower.
The US contrast agent used was SonoVue (Bracco Imaging SAS, Courcouronnes, France). The injection was administered 10 seconds before sonication. The method of delivering the contrast agent was intravenous in the ear vein as a bolus injection. The dosage used was 50 lL/kg of body weight, 9 which is the dose used in humans. The contrast agent was administered every 5 minutes because it was reported that bubbles beyond this time vanished. 24 
Statistical Analysis
Data were analyzed for statistical significance by 1-way analysis of variance. All values in each group were expressed as mean and standard deviation. All group comparisons were considered significant at P < .05.
Results
Serum total cholesterol concentrations varied from 40 to 85 mg/dL in control rabbits (n 5 3) and from 659 to 1600 mg/dL in cholesterol-fed rabbits (n 5 28). The mean in the 28 cholesterol-fed rabbits was 955 mg/dL (SD, 226 mg/dL).
As shown in Figure 2A , the opening of the BBB was depicted on contrast-enhanced T1-weighted fast spin echo MRI. The contrast-enhanced area (with an enhanced signal) corresponds to the area sonicated by the transducer (4 3 4 grid with step of 2 mm). Therefore, the volume of the BBB opening was approximately 1 3 1 3 2 cm (2 cm   3 ). This volume was calculated on the basis of the size of the 10 3 10-mm grid (plane perpendicular to the transducer beam) and the 20-mm penetration depth (plane parallel to the transducer beam), which covered a substantial portion of the right lobe of the brain. The targeting of the site shown was achieved by navigating the transducer with the positioning device. The temperature change in the brain tissue during BBB opening did not exceeded 2 8C. The beam was identified by the technique of applying a low acoustic intensity and thus detecting the beam spot with MR thermometry. In this particular figure, the target was placed in the right lobe. Similar diffused extravasation was seen in a study by McDannold et al. 25 Figure 2B shows typical hematoxylin-eosin staining of the focused US exposure used (BBB opening), showing small hemorrhage due to the level of the applied pressure.
Having confirmed with MRI that the BBB opened with the proposed US protocol, the next step was to test the various treatment options (focused US only, antibodies only, and focused US with antibodies). Figure 3A shows a coronal section of a rabbit brain, cut in the hippocampus of a control rabbit with no diet (group A), showing no plaque accumulation. Figure 3B shows a coronal section of a rabbit brain (group B), cut in the hippocampus of a high cholesterol-fed rabbit with no treatment. Figure 3C shows a coronal section of a rabbit brain, cut in the hippocampus with treatment by focused US only (group C), showing no visible destruction of plaques. Figure 3D . Figure 3E shows a coronal section of a rabbit brain with BBB opening using focused US and antibodies (group E), showing some small reduction of plaques in the right hemisphere. The plaque load decreased from 200/cm 2 (control group B) to 133/cm 2 . The plaque load was measured in an area of 1 cm 2 in the sonicated area. In the untreated area (contralateral lobe), the same area was used to measure the plaque load. Tests performed in selected rabbits using enzyme-linked immunosorbent assay kits confirmed that these plaques were Ab-42 plaques.
Before multiple sessions of BBB opening were applied, an experiment was conducted to derive the correct time that maximized the effect of exogenous antibodies. Figure 4 shows the plaque load in a rabbit brain measured at different days after treatment with focused US and antibodies and only 1 session. This result showed that the full effect of antibodies on plaque reduction was reached after 3 days.
Having established the time for maximizing the effect of antibodies, a series of experiments were conducted by varying the number of sessions of BBB opening. Figure 5A shows a coronal section of a rabbit brain, cut in the hippocampus treated with exogenous antibodies and 1 session of BBB opening using focused US. The left part of the brain included severe accumulation of Ab-42 plaques. The right part of the brain showed a substantial reduction of Ab plaques. Figure 5B shows the corresponding result with 2 sessions of BBB opening using focused US. Each session was 3 days apart. The right part of the brain showed reduction of Ab plaques compared with the case of 1 session of focused US (P < .001). Figure 5C shows the corresponding result with 3 sessions of BBB opening. The right part of the brain showed a reduction of Ab plaques compared with the case of 1 session of focused US (P < .001). In all animal groups injected with exogenous antibodies, a significant reduction in plaques was observed (P < .05; P < .001; and P < .001 for 1, 2, and 3 sessions, respectively).
These preliminary findings motivated us to acquire some more data from the histologic sections to get quantitative measurements of the reduction in the number of plaques for the different treatments (focused US only and focused US and antibodies). Figure 6 shows the distribution of plaque sizes in rabbits fed with a highcholesterol diet, with 1 session (Figure 6A ). The plaque size in humans with AD could be larger; therefore, it was possible that the efficacy of the proposed method was overestimated in this small-animal model. Figure 3 . A, Coronal section of a rabbit brain, cut in the hippocampus of a rabbit with no diet (group A). B, Coronal section of a rabbit brain, cut in the hippocampus of a control rabbit with no treatment at all (group B). C, Coronal section of a rabbit brain, cut in the hippocampus with no BBB opening and treatment with antibodies only (group C). D, Coronal section of a rabbit brain, with BBB opening using focused US (FUS) only (group D). E, Coronal section of a rabbit brain, with BBB opening using focused US and antibodies (group E). Scale bars indicate 100 lm.
The reduction in the number of plaques due to the two methods (focused US only and focused US with antibodies) is summarized in Table 2 , which shows the average number of plaques per square centimeter with standard deviations versus the treatment method (focused US only or focused US and exogenous antibodies) at different instances (control and after opening the BBB once, twice, and 3 times).
Discussion
A high-cholesterol-enriched diet produced Ab plaques in the rabbit brain, as shown previously by Sparks. 26 This useful animal model was also confirmed in this study. The molecular mechanism by which a highcholesterol diet produces Ab-like plaques is not fully understood yet. This animal model has been also used by other groups for other applications. One example was atherosclerosis, which had been reported to positively correlate with the cerebral deposition of Ab plaques in a B6Tg2576 mouse model of AD. 27 In this study, the goal was to develop an animal model for the evaluation of focused US for reducing Ab plaques.
Our study showed that the maximum size of plaques was 30 lm (Figure 3B ). The size of Ab plaques in mice as reported by Yan et al 28 was 20 lm. In a study by Prasanthi et al, 29 the plaques in rabbits were approximately 10 lm, and in another study by Sharma et al, 30 the maximum plaque size in rabbits was close to 20 lm. We cannot confirm whether the maximum plaque size was achieved because we had to euthanize the animals after 4 months to avoid distress to the rabbits. It was suggested by Serrano-Pozo et al 31 that plaques in humans reached a stable size distribution and did not substantially grew over decades. Therefore, we are not certain whether the maximum plaque size and quantity were reached.
Although dietary cholesterol has no effect on the processing of the b-amyloid precursor protein or on the production of Ab in the brain, high-cholesterol diets result in the production of Ab plaques in the brain. This finding was demonstrated in studies of cholesterol-fed animals 2, 3, 32, 33 and also confirmed by our study. A similar effect was also seen in mice fed with high-cholesterol diets. 32 A primary goal of this study was the delivery of therapy with multiple BBB openings (called sessions in this article). Each session was 3 days apart, and a maximum of 3 sessions were used. The major conclusion was that by increasing the number of sessions, the number of plaques decreased (both for the focused US-only approach and for the focused US and antibody approach). With focused US only, the number of plaques dropped from 200/cm 2 (average) to 170/cm 2 (average). The overall drop in plaques of 30/cm 2 (average) was possibly caused by the endogenous antibodies, and it was comparable to the numbers reported by Jordão et al. 14, 15 From Figure 3 one can observe that not all large plaques (>10 lm) were eliminated by focused US only. The reason that the number of plaques decreased as a result of the multiple sessions of focused US and bubbles only is possibly attributed to the fact that the body produces endogenous antibodies 15, 16 ; thus, opening the BBB frequently contributed to plaque reduction. The plaque elimination due to focused US alone, which was close to 10/cm 2 per session, is considered slow. In the future, if a patient with serious AD is treated with a phased array transducer noninvasively by multiple openings of the BBB (eg, 5-10 sessions), it may be possible to reduce the plaques for this patient without the need of any drugs.
The effect of exogenous antibodies was more drastic. With 3 sessions, the average number of plaques was reduced from 200 to 78/cm 2 . As we know, part of this reduction (nearly 30/cm 2 ) was possibly due to the endogenous antibodies, 15, 16 which entered the brain by BBB opening. The rest of the reduction was attributed to the exogenous antibodies. Jordão et al 14 showed that in some mice, a reduction in the number of plaques of almost 20% was achieved because of exogenous antibodies. The larger drop observed in our results is attributed to the multiple sessions delivered (3 sessions). If endogenous antibodies affected the results, 14 then with multiple BBB openings (3 in our study), this effect was possibly additive. It is possible to enhance the proposed treatment further by prolonging the opening of the BBB Figure 4 . Plaque load in a rabbit brain measured at different days after treatment with focused US and exogenous antibodies. Figure 5 . A, Coronal section of a rabbit brain, cut in the hippocampus treated with exogenous antibodies and 1 session of BBB opening using focused US. B, Coronal section of a rabbit brain, cut in the hippocampus treated with exogenous antibodies and 2 sessions of BBB opening using focused US. C, Coronal section of a rabbit brain, cut in the hippocampus treated with exogenous antibodies and 3 sessions of BBB opening using focused US. Scale bars indicate 100 lm.
by using repeated focused US, as proposed by Yang et al. 34 The prolongation of the BBB opening will allow more time for the antibodies to enter the brain.
Thus, this study demonstrated that by opening the BBB, it will be possible to deliver exogenous antibodies to the brain, which reduces Ab plaques. More importantly, by opening the BBB frequently (3 times in this study) the reduction in the number of plaques was accelerated. Therefore, focused US has the potential to be used noninvasively for the treatment of AD. The response seen in plaque elimination in rabbits also needs to be investigated in humans. This dramatic response observed for rabbits might not be as prominent in humans, but even a less drastic response could be very beneficial for this neurodegenerative disease. Focused US has been already proven successful for treating patients with essential tremors 35 ; therefore, it may also play a role in other neurologic diseases.
According to Mould and Sweeney, 36 the half-time of the various antibody isotopes in humans varies between 2 and 6 days (an exception is immunoglobulin G, which is 23 days). It is logical to assume that the manufacturers of animal antibodies try to produce antibodies with half-times close to humans. It was observed in our experiments that the antibodies must be allowed to react with Ab plaques for at least 3 days. Therefore, 3 days The BC-10 antibody was used.
Alecou et al-Amyloid b Plaque Reduction With Focused Ultrasound must elapse until a new session of focused US is initiated.
Since we had to euthanize the animals, it was impossible to assess whether the plaque reduction restored the neurologic deficits. Determining this outcome is a very important study that has to be done in the future. It must be proven that by reducing the plaque load, the neurologic deficits are hopefully restored.
By opening the BBB frequently, more time was allowed for the exogenous antibodies to react with the plaques; therefore, a better therapeutic result was achieved. If this application is proven successful, it may be possible in the future for patients to visit a hospital frequently on an outpatient basis and receive focused US/antibody therapy (similar to patients undergoing dialysis).
The main advantage of the rabbit model compared with the mouse model is the larger size of the brain, which provides a larger brain area and therefore possibly better focusing. Also, the plaque size in rabbits is probably larger than the plaques produced in mice. However, there are several drawbacks with the production of the rabbit model. The skull thickness for the rabbits we used varied from 2 to 3 mm. If thermal ablation were the targeted modality, it would have required high energies to create ablative temperatures in the brain, which would have resulted to severe skull heating. However, for the purpose of BBB opening, the high power used for a few milliseconds was sufficient to open the BBB. Nevertheless, regarding US transmission, the mouse model is superior because its skull thickness is smaller. Additionally, the cost of implementing the rabbit model is 5 times greater than that of the mouse model (mostly attributed to the expensive diet). Furthermore, the rabbit model requires 3 months to be fully developed, whereas the mouse model requires approximately 2 weeks. Finally, the possibility of producing Ab plaques in the mouse is quite high. From our experience, some rabbits did not produce the expected plaques.
In the future, we plan to perform experiments in a larger group of animals, thus producing sufficient statistical evidence. Moreover, in future studies, a larger group of animals will be used to assess the safety (hemorrhage and neural damage) of using multiple openings of the BBB. A long-term study, which was outside the scope of this study, is required to evaluate whether this decrease of Ab plaques restores neurologic deficits. Another improvement is to realize the attachment of antibodies to amyloid plaques by using antibody labeling. This attachment was shown by Jordão et al 14 but also needs to be demonstrated for the delivery of multiple sessions of focused US. An issue not explored in this study is the effect of the burst length. A study by McDannold et al 37 showed that the burst length plays an important role in BBB opening. Therefore, the effect of the burst length needs to be investigated more extensively. Finally, another important issue is to evaluate the effect of any other protein that could possibly enter through the BBB. This process requires extensive experimental work using proper protein labeling.
In conclusion, the main objective of this study was to remove Ab plaques by using multiple sessions of focused US-induced BBB opening using microbubbles with and without antibodies in a rabbit model. An animal model using a high-cholesterol diet in rabbits for 4 months was used. With this model, plaques of 30 lm in diameter were produced. With focused US only, the average number of plaques dropped from 200/cm . This study demonstrated that by opening the BBB, it will be possible to deliver exogenous antibodies to the brain, which eliminates Ab plaques. More importantly, by opening the BBB frequently (3 times in this study), the reduction in the number of plaques was accelerated.
